Evergreen Quality Fund GP Ltd. Reduces Stock Position in Abivax SA Sponsored ADR $ABVX

Evergreen Quality Fund GP Ltd. cut its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 22.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 224,300 shares of the company’s stock after selling 64,300 shares during the period. Abivax accounts for 0.6% of Evergreen Quality Fund GP Ltd.’s investment portfolio, making the stock its 23rd biggest position. Evergreen Quality Fund GP Ltd. owned approximately 0.28% of Abivax worth $30,248,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its position in shares of Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after acquiring an additional 369 shares in the last quarter. Bank of America Corp DE grew its position in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in shares of Abivax by 661.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares during the period. WPG Advisers LLC lifted its holdings in Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after purchasing an additional 253 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in Abivax during the 4th quarter worth about $61,000. Institutional investors own 47.91% of the company’s stock.

Abivax Price Performance

Shares of NASDAQ:ABVX opened at $100.15 on Thursday. The company’s fifty day moving average price is $114.81 and its 200-day moving average price is $118.49. The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of -19.22 and a beta of 0.69. Abivax SA Sponsored ADR has a one year low of $5.69 and a one year high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, equities research analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ABVX. Citizens Jmp lifted their target price on Abivax from $131.00 to $187.00 and gave the company a “market outperform” rating in a report on Tuesday, June 2nd. Wolfe Research set a $136.00 price objective on shares of Abivax in a research report on Wednesday, June 3rd. BTIG Research reaffirmed a “buy” rating and set a $150.00 price objective on shares of Abivax in a research note on Tuesday. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a report on Tuesday, June 2nd. Finally, Wedbush raised shares of Abivax from an “underperform” rating to a “neutral” rating and cut their price target for the company from $110.00 to $90.00 in a report on Tuesday, June 2nd. Twelve investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $130.08.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.